Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06516510 · ClinicalTrials.gov registry record · Early Phase 1
A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer
A Early Phase 1 study, sponsored by Blue Earth Therapeutics.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 17
- Enrollment target
NCT06516510: Clinical Trial Early Phase 1 study, sponsored by Blue Earth Therapeutics.
NCT06516510 is a Early Phase 1 study that was terminated before completion, run by Blue Earth Therapeutics. The registered enrollment target is 17 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06516510, a Early Phase 1 study, was terminated before completion, sponsored by Blue Earth Therapeutics.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
A randomised, multi-centre, intra-patient imaging and dosimetry crossover study of lutetium (177Lu) rhPSMA 10.1 and lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) in patients with non-curative metastatic prostate cancer
Interventions
- DRUG lutetium (177Lu) rhPSMA 10.1 and Pluvicto®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2024-10-31 |
| Est. Completion | 2025-08-15 |
| Phase | Early Phase 1 |
Why NCT06516510 stopped before completion
NCT06516510 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 1 intervention - of which lutetium (177Lu) rhPSMA 10.1 and Pluvicto® is the first listed.
NCT06516510 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06516510 about?
NCT06516510 is a clinical study titled "A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer". A randomised, multi-centre, intra-patient imaging and dosimetry crossover study of lutetium (177Lu) rhPSMA 10.1 and lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) in patients with non-curative metastatic prostate cancer
What is the current status of trial NCT06516510?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 17 participants. The study started on 2024-10-31. Estimated completion is 2025-08-15.
What interventions are being tested in trial NCT06516510?
The interventions under investigation include: lutetium (177Lu) rhPSMA 10.1 and Pluvicto® (DRUG).
Who is sponsoring clinical trial NCT06516510?
This trial is sponsored by Blue Earth Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06516510's enrollment target sits among peer trials
17 1350th of 2000 higher than 632 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI